Wolfgang Willenbacher

5.0k total citations · 2 hit papers
112 papers, 2.9k citations indexed

About

Wolfgang Willenbacher is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Wolfgang Willenbacher has authored 112 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 56 papers in Hematology and 33 papers in Pathology and Forensic Medicine. Recurrent topics in Wolfgang Willenbacher's work include Multiple Myeloma Research and Treatments (45 papers), Lymphoma Diagnosis and Treatment (32 papers) and Chronic Lymphocytic Leukemia Research (17 papers). Wolfgang Willenbacher is often cited by papers focused on Multiple Myeloma Research and Treatments (45 papers), Lymphoma Diagnosis and Treatment (32 papers) and Chronic Lymphocytic Leukemia Research (17 papers). Wolfgang Willenbacher collaborates with scholars based in Austria, United States and Germany. Wolfgang Willenbacher's co-authors include Vânia Hungria, Andrew Spencer, Saroj Vadhan‐Raj, David H. Henry, Jana Prausová, Roger Dansey, Jianming Wang, Luís Costa, H.P. Sleeboom and Qi Jiang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Wolfgang Willenbacher

105 papers receiving 2.8k citations

Hit Papers

Randomized, Double-Blind Study of Denosumab Versus Zoledr... 2011 2026 2016 2021 2011 2018 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
    2011 877 citations Wolfgang Willenbacher et al. Journal of Clinical Oncology profile →
  2. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
    2018 307 citations Wolfgang Willenbacher et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wolfgang Willenbacher Austria 21 1.7k 813 594 545 457 112 2.9k
Jan S. Moreb United States 32 1.6k 0.9× 926 1.1× 1.2k 2.0× 264 0.5× 302 0.7× 123 3.3k
Stephanie de Bono United States 19 683 0.4× 893 1.1× 261 0.4× 313 0.6× 543 1.2× 49 3.0k
Michele Nichelatti Italy 24 1.2k 0.7× 262 0.3× 534 0.9× 714 1.3× 401 0.9× 108 3.9k
Barbara L. Asselin United States 37 1.1k 0.7× 873 1.1× 690 1.2× 481 0.9× 157 0.3× 83 5.1k
Kadri Altundağ Türkiye 30 2.5k 1.4× 109 0.1× 717 1.2× 339 0.6× 201 0.4× 251 3.9k
Ben Sprangers Belgium 38 589 0.3× 450 0.6× 561 0.9× 298 0.5× 213 0.5× 175 4.3k
Sriram Krishnaswami United States 32 1.4k 0.8× 2.2k 2.7× 414 0.7× 489 0.9× 1.3k 2.8× 59 6.1k
Rolf Rau Germany 23 298 0.2× 963 1.2× 405 0.7× 310 0.6× 394 0.9× 39 3.3k
Anthony Sebba United States 19 493 0.3× 456 0.6× 346 0.6× 142 0.3× 189 0.4× 37 2.0k
Jonathan S. Coblyn United States 22 312 0.2× 556 0.7× 690 1.2× 145 0.3× 186 0.4× 31 2.6k

Countries citing papers authored by Wolfgang Willenbacher

Since Specialization
Citations

This map shows the geographic impact of Wolfgang Willenbacher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfgang Willenbacher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfgang Willenbacher more than expected).

Fields of papers citing papers by Wolfgang Willenbacher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wolfgang Willenbacher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfgang Willenbacher. The network helps show where Wolfgang Willenbacher may publish in the future.

Co-authorship network of co-authors of Wolfgang Willenbacher

This figure shows the co-authorship network connecting the top 25 collaborators of Wolfgang Willenbacher. A scholar is included among the top collaborators of Wolfgang Willenbacher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wolfgang Willenbacher. Wolfgang Willenbacher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dejaco, Daniel, Wolfgang Willenbacher, Andreas Meryk, et al.. (2025). Implementierung von ePROs in der Onkologie. 31(12). 1231–1242.
2.
Thurner, Gudrun C., et al.. (2023). In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation. Annals of Hematology. 103(2). 553–563. 1 indexed citations
3.
Lehmann, Jens, Kelly M. de Ligt, Johannes M. Giesinger, et al.. (2023). Adherence to Patient-Reported Symptom Monitoring and Subsequent Clinical Interventions for Patients With Multiple Myeloma in Outpatient Care: Longitudinal Observational Study. Journal of Medical Internet Research. 25. e46017–e46017. 6 indexed citations
4.
Brunner, Andrea, B. Zelger, Ella Willenbacher, et al.. (2023). Deep learning analysis of mid‐infrared microscopic imaging data for the diagnosis and classification of human lymphomas. Journal of Biophotonics. 16(11). e202300015–e202300015. 3 indexed citations
5.
Hoffmann, Christian, Marcus Hentrich, Markus Tiemann, et al.. (2022). Recent Advances in Castleman Disease. Oncology Research and Treatment. 45(11). 693–704. 15 indexed citations
6.
Jukic, Emina, Markus A. Keller, Irmgard Verdorfer, et al.. (2022). Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma. European Journal Of Haematology. 110(3). 296–304. 6 indexed citations
7.
Lehmann, Jens, Johannes M. Giesinger, Lisa M. Wintner, et al.. (2021). Using the Computer-based Health Evaluation System (CHES) to Support Self-management of Symptoms and Functional Health: Evaluation of Hematological Patient Use of a Web-Based Patient Portal. Journal of Medical Internet Research. 23(6). e26022–e26022. 16 indexed citations
8.
Koinig, Karin A., C. Arnold, Jens Lehmann, et al.. (2021). The cancer patient’s perspective of COVID‐19‐induced distress—A cross‐sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic. Cancer Medicine. 10(12). 3928–3937. 29 indexed citations
9.
Willenbacher, Ella, Andrea Brunner, Bettina Zelger, et al.. (2021). Application of mid‐infrared microscopic imaging for the diagnosis and classification of human lymphomas. Journal of Biophotonics. 14(9). e202100079–e202100079. 10 indexed citations
10.
Willenbacher, Ella, Andrea Brunner, Wolfgang Willenbacher, et al.. (2020). Visible and near-infrared hyperspectral imaging techniques allow the reliable quantification of prognostic markers in lymphomas: A pilot study using the Ki67 proliferation index as an example. Experimental Hematology. 91. 55–64. 8 indexed citations
11.
Willenbacher, Ella, Shah Zeb Khan, Dario Trapani, et al.. (2019). Curcumin: New Insights into an Ancient Ingredient against Cancer. International Journal of Molecular Sciences. 20(8). 1808–1808. 121 indexed citations
12.
Ludwig, Heinz, Stefan Knop, Alexander Egle, et al.. (2019). Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. British Journal of Cancer. 121(9). 751–757. 17 indexed citations
13.
Nowakowski, Grzegorz S., Wolfgang Willenbacher, Richard Greil, et al.. (2019). Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.. Journal of Clinical Oncology. 37(15_suppl). 7520–7520. 10 indexed citations
14.
Ramchandren, Radhakrishnan, Michelle A. Fanale, Antonio Rueda, et al.. (2017). Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study. Blood. 130(Suppl_1). 651–651. 22 indexed citations
15.
Steiner, Normann, Roman Hájek, Karin Jöhrer, et al.. (2017). Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma. Oncotarget. 8(34). 56243–56254. 16 indexed citations
16.
Buchberger, Maria, Ursula Rochau, Wolfgang Willenbacher, et al.. (2016). Comparative Effectiveness of Treatment Strategies For Multiple Myeloma in Elderly Patients: A Network Meta-Analysis. Value in Health. 19(7). A710–A710. 1 indexed citations
17.
Subbiah, Vivek, Yung‐Jue Bang, Ulrik Lassen, et al.. (2016). ROAR: a phase 2, open-label study in patients (pts) with BRAF V600E–mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy.. Journal of Clinical Oncology. 34(15_suppl). TPS2604–TPS2604. 9 indexed citations
18.
Steiner, Normann, David Nachbaur, Paul König, Wolfgang Willenbacher, & Eberhard Gunsilius. (2015). Long-term control in a patient with refractory multiple myeloma by oral cyclophosphamide and dexamethasone.. PubMed. 35(4). 2165–8. 4 indexed citations
19.
Buchberger, Maria, et al.. (2015). TREATMENT STRATEGIES FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A META-ANALYSIS AND INDIRECT TREATMENT COMPARISON. Value in Health. 18(7). A432–A432. 1 indexed citations
20.
Fiegl, Michael, Günther Steger, Michael Studnicka, et al.. (2013). Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study. Current Medical Research and Opinion. 29(5). 505–515. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan S. Moreb Breakdown of academic impact, for papers by Stephanie de Bono Breakdown of academic impact, for papers by Michele Nichelatti Breakdown of academic impact, for papers by Barbara L. Asselin Breakdown of academic impact, for papers by Kadri Altundağ Breakdown of academic impact, for papers by Ben Sprangers Breakdown of academic impact, for papers by Sriram Krishnaswami Breakdown of academic impact, for papers by Rolf Rau Breakdown of academic impact, for papers by Anthony Sebba Breakdown of academic impact, for papers by Jonathan S. Coblyn
Rankless by CCL
2026